Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Forero-Torres, A., Berryman, R. B., Advani, R. H., Bartlett, N. L., Chen, R. W., Fanale, M. A., Gopal, A. K., O'Connor, O. A., Olshefski, R., Smith, S. E., Grove, L. E., Matous, J. AMER SOC HEMATOLOGY. 2011: 1585–86
View details for Web of Science ID 000299597105439